Drugs / 89-Zirconium (Zr-89) Panitumumab
89-Zirconium (Zr-89) Panitumumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03733210 | Jan 2019 → Dec 2020 | head and neck squamous cell carcinoma | Andrei Iagaru | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89-Zirconium (Zr-89) Panitumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03733210 ↗ |
| Modality | Diagnostic / imaging agent | “89Zr-panitumumab is a drug that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans.” NCT03733210 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT03733210 ↗ |